Wintrust Investments LLC Boosts Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Wintrust Investments LLC boosted its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 86.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,937 shares of the biopharmaceutical company’s stock after buying an additional 900 shares during the quarter. Wintrust Investments LLC’s holdings in Madrigal Pharmaceuticals were worth $597,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the company. Kohmann Bosshard Financial Services LLC bought a new position in shares of Madrigal Pharmaceuticals during the 4th quarter worth $70,000. Quest Partners LLC boosted its position in Madrigal Pharmaceuticals by 172.8% during the third quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 368 shares during the period. KBC Group NV increased its stake in shares of Madrigal Pharmaceuticals by 73.5% in the fourth quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 258 shares in the last quarter. Miracle Mile Advisors LLC purchased a new position in shares of Madrigal Pharmaceuticals in the fourth quarter worth about $216,000. Finally, D.A. Davidson & CO. bought a new stake in shares of Madrigal Pharmaceuticals in the fourth quarter valued at approximately $221,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

Madrigal Pharmaceuticals Stock Performance

NASDAQ MDGL opened at $327.31 on Thursday. The company has a fifty day moving average of $325.79 and a 200-day moving average of $289.37. Madrigal Pharmaceuticals, Inc. has a 52-week low of $189.00 and a 52-week high of $377.46. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. The company has a market capitalization of $7.23 billion, a P/E ratio of -13.05 and a beta of -0.41.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) EPS for the quarter, beating the consensus estimate of ($4.32) by $1.61. The firm had revenue of $103.32 million for the quarter, compared to the consensus estimate of $97.81 million. As a group, equities research analysts predict that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on MDGL. B. Riley raised Madrigal Pharmaceuticals from a “hold” rating to a “strong-buy” rating and raised their price target for the stock from $236.00 to $422.00 in a report on Thursday, February 27th. HC Wainwright increased their price objective on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. Citigroup lifted their target price on Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 20th. Finally, JMP Securities restated a “market outperform” rating and issued a $427.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $375.75.

Insider Transactions at Madrigal Pharmaceuticals

In other news, insider Carole Huntsman sold 347 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $116,328.28. Following the sale, the insider now directly owns 10,438 shares in the company, valued at approximately $3,499,235.12. This trade represents a 3.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Rebecca Taub sold 1,689 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $273.41, for a total value of $461,789.49. Following the transaction, the chief marketing officer now owns 457,310 shares of the company’s stock, valued at approximately $125,033,127.10. This represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 35,900 shares of company stock worth $12,168,079. Insiders own 22.80% of the company’s stock.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.